Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure
ObjectiveTo investigate the changes in the serum levels of interleukin-32 (IL-32) and interleukin-10 (IL-10) and their clinical significance in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF). MethodsA total of 38 HBV-ACLF patients who were hospitalized and treated in The First A...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2018-04-01
|
Series: | Linchuang Gandanbing Zazhi |
Subjects: | |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8902 |
id |
doaj-2a7ed6b3c4b244c99cb2ce126cf594c8 |
---|---|
record_format |
Article |
spelling |
doaj-2a7ed6b3c4b244c99cb2ce126cf594c82020-11-24T22:56:53ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562018-04-0134480180510.3969/j.issn.1001-5256.2018.04.021Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failureGU Jing0WANG YanCHEN LiDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, ChinaObjectiveTo investigate the changes in the serum levels of interleukin-32 (IL-32) and interleukin-10 (IL-10) and their clinical significance in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF). MethodsA total of 38 HBV-ACLF patients who were hospitalized and treated in The First Affiliated Hospital of Soochow University from September 2012 to March 2014 were enrolled as HBV-ACLF group, as well as 20 patients with chronic hepatitis B (CHB) (CHB group) and 20 healthy controls (healthy control group). ELISA was used for dynamic monitoring of the changes in the serum levels of IL-32 and IL-10. The serum levels of IL-32 and IL-10 were compared between early-, middle-, and late-stage HBV-ACLF groups, between infection group and non-infection group, and between survival group and death group. The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups. ResultsCompared with the CHB group and the healthy control group, the HBV-ACLF group had significantly higher levels of IL-32 (50098±152.33 pg/ml vs 281.72±99.28 pg/ml and 178.16±50.54 pg/ml, both P<0.05) and IL-10 (4.82±1.03 pg/ml vs 3.15±0.98 pg/ml and 1.62±0.43 pg/ml, both P<0.05). Dynamic monitoring of IL-32 level in the HBV-ACLF group showed that the early-stage HBV-ACLF group had a significantly higher level than the middle-stage HBV-ACLF group (540.69±155.71 pg/ml vs 498.43±135.56 pg/ml, P<0.05), and the middle-stage HBV-ACLF group had a significantly higher level than the late-stage HBV-ACLF group (498.43±135.56 pg/ml vs 450.77±102.33 pg/ml, P<0.05); as for the level of IL-10, the early-stage HBV-ACLF group had a significantly lower level than the middle-stage HBV-ACLF group (1.94±0.44 pg/ml vs 2.83±0.97 pg/ml, P<0.05), and the middle-stage HBV-ACLF group had a significantly lower level than the late-stage HBV-ACLF group (2.83±0.97 pg/ml vs 3.69±123 pg/ml, P<0.05). The HBV-ACLF infection group had a significantly higher level of IL-32 than the non-infection group (553.41±158.65 pg/ml vs 48254±110.16 pg/ml, P=0.021). Compared with the HBV-ACLF death group, the HBV-ACLF survival group had a significantly lower level of IL-32 (481.95±100.67 pg/ml vs 540.62±112.45 pg/ml, P=0.011) and a significantly higher level of IL-10 (4.21±1.27 pg/ml vs 3.61±1.05 pg/ml, P=0.038). ConclusionThe cytokine network plays an important role in the pathogenesis of HBV-ACLF. Serum IL-32 and IL-10 may be involved in disease progression, and dynamic monitoring of their levels helps with prognostic prediction.http://www.lcgdbzz.org/qk_content.asp?id=8902liver failure; hepatitis B virus; interleukin-10; interleukin-32 |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
GU Jing WANG Yan CHEN Li |
spellingShingle |
GU Jing WANG Yan CHEN Li Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure Linchuang Gandanbing Zazhi liver failure; hepatitis B virus; interleukin-10; interleukin-32 |
author_facet |
GU Jing WANG Yan CHEN Li |
author_sort |
GU Jing |
title |
Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure |
title_short |
Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure |
title_full |
Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure |
title_fullStr |
Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure |
title_full_unstemmed |
Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure |
title_sort |
changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with hbv-related acute-on-chronic liver failure |
publisher |
Editorial Department of Journal of Clinical Hepatology |
series |
Linchuang Gandanbing Zazhi |
issn |
1001-5256 1001-5256 |
publishDate |
2018-04-01 |
description |
ObjectiveTo investigate the changes in the serum levels of interleukin-32 (IL-32) and interleukin-10 (IL-10) and their clinical significance in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF). MethodsA total of 38 HBV-ACLF patients who were hospitalized and treated in The First Affiliated Hospital of Soochow University from September 2012 to March 2014 were enrolled as HBV-ACLF group, as well as 20 patients with chronic hepatitis B (CHB) (CHB group) and 20 healthy controls (healthy control group). ELISA was used for dynamic monitoring of the changes in the serum levels of IL-32 and IL-10. The serum levels of IL-32 and IL-10 were compared between early-, middle-, and late-stage HBV-ACLF groups, between infection group and non-infection group, and between survival group and death group. The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups. ResultsCompared with the CHB group and the healthy control group, the HBV-ACLF group had significantly higher levels of IL-32 (50098±152.33 pg/ml vs 281.72±99.28 pg/ml and 178.16±50.54 pg/ml, both P<0.05) and IL-10 (4.82±1.03 pg/ml vs 3.15±0.98 pg/ml and 1.62±0.43 pg/ml, both P<0.05). Dynamic monitoring of IL-32 level in the HBV-ACLF group showed that the early-stage HBV-ACLF group had a significantly higher level than the middle-stage HBV-ACLF group (540.69±155.71 pg/ml vs 498.43±135.56 pg/ml, P<0.05), and the middle-stage HBV-ACLF group had a significantly higher level than the late-stage HBV-ACLF group (498.43±135.56 pg/ml vs 450.77±102.33 pg/ml, P<0.05); as for the level of IL-10, the early-stage HBV-ACLF group had a significantly lower level than the middle-stage HBV-ACLF group (1.94±0.44 pg/ml vs 2.83±0.97 pg/ml, P<0.05), and the middle-stage HBV-ACLF group had a significantly lower level than the late-stage HBV-ACLF group (2.83±0.97 pg/ml vs 3.69±123 pg/ml, P<0.05). The HBV-ACLF infection group had a significantly higher level of IL-32 than the non-infection group (553.41±158.65 pg/ml vs 48254±110.16 pg/ml, P=0.021). Compared with the HBV-ACLF death group, the HBV-ACLF survival group had a significantly lower level of IL-32 (481.95±100.67 pg/ml vs 540.62±112.45 pg/ml, P=0.011) and a significantly higher level of IL-10 (4.21±1.27 pg/ml vs 3.61±1.05 pg/ml, P=0.038). ConclusionThe cytokine network plays an important role in the pathogenesis of HBV-ACLF. Serum IL-32 and IL-10 may be involved in disease progression, and dynamic monitoring of their levels helps with prognostic prediction. |
topic |
liver failure; hepatitis B virus; interleukin-10; interleukin-32 |
url |
http://www.lcgdbzz.org/qk_content.asp?id=8902 |
work_keys_str_mv |
AT gujing changesinserumlevelsofinterleukin32andinterleukin10andtheirclinicalsignificanceinpatientswithhbvrelatedacuteonchronicliverfailure AT wangyan changesinserumlevelsofinterleukin32andinterleukin10andtheirclinicalsignificanceinpatientswithhbvrelatedacuteonchronicliverfailure AT chenli changesinserumlevelsofinterleukin32andinterleukin10andtheirclinicalsignificanceinpatientswithhbvrelatedacuteonchronicliverfailure |
_version_ |
1725652807340523520 |